Advanced Cell Technology achieves strongest financial position yet Print E-mail
By Deborah Sterescu,   
Monday, 21 March 2011 10:35
Stem cell-focused Advanced Cell Technology (OTCBB:ACTC) said Monday that it ended 2010 with significantly more cash at its hands and less debt - representing the company's strongest financial position yet.
At year-end, the company had $15.9 million in cash and equivalents and less than $1 million in debt, compared to $2.5 million in cash and equivalents and $8.4 million in debt during the year-ago period.

Since September 2009, the company has been focused on improving its balance sheet by eliminating more than $34 million in loans, including $20 million in the most recent quarter. Advanced Cell Technology said that it now anticipates having enough cash to fund operations through mid-2012.

Indeed, the company will need the cash, as 2010 saw significant operational progress for the stem cell pioneer.

Late last year, the regenerative medicine company received FDA clearance to begin phase I/II trials to treat Stargardt's Macular Dystrophy, a degenerative eye disease seen in younger patients. The company's treatment, which already received orphan drug status in the US, uses retinal cells derived from human embryonic stem cells.

In addition, the company also received clearance to test the stem cell treatment for patients with dry age-related macular degneration, which afflicts between 10 and 15 million Americans and as many Europeans.

"While receiving these clearances represented a tremendous achievement for the company, our ability to dramatically improve our balance sheet was equally important, as we now have the ability to complete these two trials without seeking additional capital," said interim chairman and CEO Gary Rabin. 

In 2010, Advanced Cell used $8.8 million in cash for operations, compared to $5.1 million in 2009, due primarily to new drug application filings, it said.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus